CD19 and diffuse large B-cell lymphoma: Epcoritamab and glofitamab are currently effective new additions to the therapeutic arsenal for patients with R/R DLBCL in the third-line setting with a manageable safety profile, notably in patients who previously received treatment with CD19-targeting CAR T-cells.